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ABSTRACT
Background: Nitric oxide (NO) turnover is vital for proper endothelial function to maintain a healthy vascular 
system. Various risk factors responsible for hypertension and diabetes may disrupt this homeostasis, leading to 
decreased bioavailability and/or bioactivity of NO, which potentiates endothelial dysfunction. Plasma NO is a 
useful indicator of NO homeostasis and vascular endothelial function. Since endothelial function plays a key 
role in the development and progression of diseases like diabetes and hypertension, we sought to investigate 
the NO profile in patients having diabetes and hypertension and determine the relationship of NO turnover 
with the disease. Materials and Methods: For this purpose, three groups were studied for the NO production. 
The first group consisted of 74 hypertensive patients, the second group consisted of 72 diabetic patients and 
the third group consisted of 60 healthy controls. Nitrate synthase activity was evaluated by measuring nitrate 
level using an automated sample injector connected to an automated NO detector – Ion liquid chromatograph.  
Results: The plasma concentration of NO was found to be significantly lower in both essential hypertensive 
patients and diabetic patients without complications as compared to the healthy controls (P < 0.05). Conclusion: 
This data confirms that different factors like hyperglycemia and blood pressure are seen to have immense 
influence on NO production.
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l-citrulline and NO.[2,3] Three isoforms of NOS, specific 
to different organ systems, exist. Apart from playing 
an important role in vasodilation, NO is also critically 
involved in the regulation of other protective properties 
of the healthy endothelium by playing an important role 
in a wide range of physiological processes like platelet 
and leukocyte aggregation,[4] leukocyte adhesion,[5] cell 
proliferation and vasoconstriction.[6,7] Evidence suggests 
that NO plays a major role in regulating blood pressure and 
glucose levels, and thus impaired NO bioactivity forms an 
important component of hypertension and diabetes. The 
physiological importance of NO in the regulation of blood 
pressure is evidenced by the fact that pharmacological 
inhibition of NO synthases leads to severe hypertension, 
vascular injury, and glomerulosclerosis in experimental 
animals.[8] Moreover, endothelial NOS (eNOS) knockout 
mice exhibit hypertension,[9] thus providing further 
Access this article online
Quick Response Code:
Website:
www.jcdronline.com
DOI:
10.4103/0975-3583.85264 
INTRODUCTION
Endothelium, which is an inert single-cell lining covering 
the internal surface of blood vessels, plays a crucial role 
in vascular homeostasis by regulating vascular tone and 
structure.[1] Nitric oxide (NO) is the most pivotal molecule 
secreted by endothelium and thus is a major mediator of 
endothelial function. The production of NO is catalyzed 
by family of enzymes called as nitric oxide synthases 
(NOS), which convert the amino acid l-arginine to 173 Journal of Cardiovascular Disease Research Vol. 2 / No 3
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support for the importance of NO in the regulation of 
blood pressure. Likewise, in diabetic subjects also, it has 
been demonstrated that the vasodilating response to 
stimuli is diminished and that this anomaly is related to 
glycemic control.[10] In vivo studies have demonstrated that 
hyperglycemic spikes induce an endothelial dysfunction 
in both diabetic and normal subjects.[11-13] Moreover, 
a significant association between eNOS gene polymorphisms 
and type 2 diabetes suggests a genetic link between NO 
production and diabetes.[14] Endothelial dysfunction is 
associated with disruption of vascular homeostasis leading 
to proinflammatory and prothrombotic phenotype of 
the endothelium; thus, it may play a pivotal role in the 
development and progression of secondary complications 
both in diabetes and hypertension.
While it is apparent that NO turnover has a definitive 
influence on the etiology of many common disorders, 
much remains to be done to substantiate NO targeted 
therapies for the treatment of such disorders. Likewise, 
a systematic detail of ascertaining the relationship 
of NO dynamics with such disorders needs to be 
elucidated before NO-targeted therapeutic proposition is 
considered. As NO rapidly changes into stable oxidized 
metabolites, such as nitrite and nitrate, in all parts of the 
body, the amount of the stable form in plasma should 
reflect vascular activities and circulatory changes in the 
body. Therefore, pathophysiological changes such as 
atherosclerosis, endothelial dysfunction, pro-inflammation 
and inflammation seen in diabetic and hypertensive patients 
may be understood by measuring NO metabolites in the 
peripheral blood. Our study is an attempt to measure NO 
metabolite (NOx: nitrate) in the serum of normotensive 
controls, diabetic subjects and hypertensive subjects and 
analyze it in relation to the effects of disease.
MATERIALS AND METHODS
Study design
The study was conducted on 74 hypertensive patients (40 
men, 34 women; mean age of 55±10 years), 72 diabetic 
patients without complications (37 men, 35 women; mean 
age of 55±10 years) and 60 healthy volunteers (33 men, 27 
women) from a similar ethnic background without any health 
problems (aged 45–65 years) who served as healthy controls.
Both hypertension and type 2 diabetes were diagnosed 
according to the criteria of the World Health Organization. 
Normal blood pressure was defined as systolic blood 
pressure (SBP) <140 mm Hg and diastolic blood pressure 
(DBP) <90 mm Hg. Hypertension was defined as either 
SBP ≥160 mm Hg or DBP of ≥95 mm Hg, or both, 
with a well-documented history of long-term high blood 
pressure. Patients were excluded if they had any history 
of certain vascular complications (i.e., cardiac, cerebral, or 
peripheral vascular diseases), congestive heart failure, renal 
dysfunction (serum creatinine concentration > 1.5 mg/
dl), malignancy, or hematological diseases, and if they had 
taken any antihypertensive/hyperlipidemic medications 
such as angiotensin converting enzyme inhibitors (ACEI)/
statins that might influence NO levels. Participants were 
instructed to refrain from eating for 18 hours, drinking 
beverages containing alcohol or caffeine, or smoking for 
at least 24 hours before blood sampling.
To exclude the aging effect possible, only those aged less 
than 65 years were examined. The samples to be assayed 
were taken from those who agreed with the experimental 
use of the research, and a signed informed consent was 
obtained from all the patients who participated in the study.
Analytical methods
About 2 ml of whole blood was drawn from each subject 
into heparinized tubes, which were promptly chilled in an 
ice bath. Plasma was isolated by centrifugation (15 min at 
13,000 rpm) and then stored at −80°C till further analysis. 
For deproteinization, equal amount of acetonitrile was 
added to the plasma followed by centrifugation at 13,000 
rpm for 30 min. The supernatant was collected and pellet 
discarded. The samples obtained were kept at −80°C until 
the time of NO metabolite analysis. Nitrate level in the 
plasma samples was measured using an automated sample 
injector connected to an automated NO detector – Ion 
liquid chromatograph (Dionex, Model ICS-2500).
Statistical methods
The entire data was statistically analyzed using SPSS 
program. Data were expressed as the mean±SEM and were 
compared by analysis of variance. P < 0.05 was considered 
statistically significant.
RESULTS
The clinical characteristics of hypertensive, diabetic and 
normal control subjects are summarized in Table 1. With the 
exception of  systemic blood pressure (measured at the time 
of the study) in case of hypertensive subjects, no significant 
difference in these characteristics was observed between the 
patient and control groups. The average plasma nitrate level 
in essential hypertensive patients was 39.7±13.27 µmol/L 
(range 30.855–46.63 µmol/L), which showed significant 174 Journal of Cardiovascular Disease Research Vol. 2 / No 3
Ayub, et al.: Nitrate level in hypertension and diabetes
difference compared to the normotensive healthy group 
(100.48±32.46 µmol/L). Patients having diabetes without 
complications had a plasma nitrate level of 24.95±15.79 
µmol/L (range 16.808–30.748 µmol/L), which is also 
significantly less compared to the control group [Table 2].
DISCUSSION
The inverse correlation between the plasma nitrate 
concentration and hypertensive group makes it imperative 
that blood pressure plays an important role in the 
downregulation of NO production in these subjects. 
The observations concerning the end product of NO 
metabolites are non-univocal in hypertension; many reports 
in fact show their decrease, while others demonstrate their 
increase. However, our results are in agreement with data 
showing the inverse correlation between the two. A study 
conducted on hypertensive patients has shown decreased 
level of NOx and guanosine 3’,5’-cyclic monophosphate 
(cGMP) compared to normotensive subjects, and 
antihypertensive agents such as calcium channel blockers or 
ACEI were effective in recovering those levels.[15] It has been 
seen that SBP and DBP inversely correlated with plasma 
and urinary nitrate owing to the decline of antioxidative 
activity (i.e., lipid peroxidation enhanced by the lack of 
antioxidant activities) which was associated with decreased 
NO production and the severity of hypertension.[16] Li   
et al, reported a positive association between NOx and 
BP in normotensive African Americans who carry the   
“a” allele of eNOS4 polymorphism.[17]
Hypertension can produce structural damage to aortic 
endothelial cells in animals, and pressure overload is 
associated with a direct toxic effect on human endothelium; 
impairment of the release of NO from vascular 
endothelial cells may thus contribute to the reduced plasma 
nitrogen oxide concentrations in patients with essential 
hypertension. Decreased synthesis of NO might also result 
from abnormal handling of intracellular calcium and a 
consequent reduction in the activity of NOS.[18] Increased 
production of superoxide anions in oxidative stress 
which rapidly deactivate NO is a characteristic feature of  
experimental models of hypertension.[19,20] It is also seen 
that plasma indexes of lipid peroxidation are increased 
in patients with hypertension.[21] Studies have shown that 
hypertension impairs endothelium-dependent dilation 
of rat coronary arteries as a result of superoxide anion 
mediated degradation of NO.[19] Mice with disruption of 
the gene for eNOS have elevated BP levels compared with 
control animals, suggesting a genetic component to the 
link between impaired NO bioactivity and hypertension.[22]
Our results also showed inverse correlation between NO 
level and diabetic state and this fact clearly underlines that 
hyperglycemia is a major determinant factor in serum NOx 
levels. It is widely recognized that hyperglycemia induces 
impairment of the endothelial function via increased 
oxidative stress[23] which is a characteristic feature of 
diabetic individuals. The hyperglycemic state stimulates 
the production of advanced glycosylated end products,[24] 
enhances the polyol pathway[25] and activates protein kinase 
C leading to oxidative stress.[26,27] A reduced content of 
glutathione, an important antioxidant in erythrocytes, 
Table 1: Clinical characteristics of the study groups
Characteristic Control Hypertension Diabetes
No. of patients (men/women) 60 (33/27) 74 (40/34) 72 (37/35)
Age, years 55±10 55±10 55±10
Systolic blood pressure, mm Hg 128±4 159±5 128±4
Diastolic blood pressure, mm Hg 71±3 101±4 71±3
Heart rate, beats per minute 69±2 68±3 68±3
Body mass index, kg/m2 25±2.5 26±2 25±3.6
Waist to hip ratio 0.9±0.05 0.9±0.04 0.96±0.049
Serum cholesterol, mmol/L 4.5±0.9 4.7±0.55 4.6±1.2
Serum HDL, mmol/L 1.1±0.5 1.2±0.4 1.1±0.32
Serum LDL, mmol/L 2.0±0.5 2.1±1.1 2.3±1.25
Serum VLDL, mmol/L 0.8±0.05 0.9±0.05 1.17±0.4
Serum triglycerides, mmol/L 1.6±0.4 1.7±0.5 2.66±0.94
Serum creatinine, µmol/L 61±17 62±18 59.6±20.4
Blood urea nitrogen, mmol/L 8.2±2 8±2.3 8.3±2.5
Serum uric acid mmol/L 0.4±0.12 0.38±0.12 0.34±0.13
Table 2: Mean nitrate level of patients with essential hypertension, diabetes and control subjects
Control subjects (n = 60) Essential hypertensive subjects (n = 74) Diabetic subjects (n = 72)
Nitrate level 100.48±32.46 µmol/L 39.7±13.27 µmol/L 24.95±15.79 µmol/L175 Journal of Cardiovascular Disease Research Vol. 2 / No 3
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has been demonstrated in diabetic patients.[28,29] Also, 
reduced radical-trapping antioxidant parameter (TRAP) 
and increased lipid peroxidation levels support the in vivo 
presence of increased oxidative stress in diabetes.[30-32] 
Reduced NO availability may not only be of relevance 
to the development of atherosclerotic complications 
in diabetes, but also interfere with insulin-mediated 
postprandial glucose disposal and possibly contribute to 
the development of insulin resistance.
Various studies have reported a significant decrease of 
plasma nitric oxides in patients with type 2 diabetes 
mellitus without any complications.[33,34] Decreased NO 
bioavailability to smooth muscle cells in no complicated 
group has also been demonstrated in different studies.[35] 
Our results coincide with these reports, and we presumed 
that the cascade of NO bioactivity and availability on 
smooth muscle cells was impaired in the early affected 
stage of diabetes mellitus and followed the decrease of 
endothelial NO production.
Reduced NO availability in diabetes mellitus and 
hypertension underlines its relevance to the development 
of secondary complications in these clinical conditions. 
Alteration of NO metabolism and increased oxidant 
stress, previously demonstrated in diabetic patients, have 
been demonstrated to be involved in the pathogenesis of 
macrovascular events, which are increased in hypertensive 
as well as diabetic patients.[36-39]
To the horizon of our knowledge, our work represents the 
first study of this kind done in Kashmir, India. Moreover, 
the distinct features of Kashmir including unique 
geographic locale, traditions, culture and genetically pure 
and ethnic population prompted us to take this particular 
study and compare NO levels in diseased and normal 
states. Our study is a preliminary attempt to investigate 
the correlation of NO turnover with diabetes and 
hypertension. However, further studies need to be done 
to gain information for better understanding of the key 
events relevant to the designing and establishing the role of 
NO assays in diabetes and hypertension. In conclusion, our 
findings indicate that NO concentrations were significantly 
lower in men and women with essential hypertension and 
type II diabetes, supporting the hypothesis that altered 
NO pathway is a central defect leading to diabetes and 
hypertension. The inverse correlation observed in this 
cohort of population is in agreement with the observations 
of some of our global peers, while other studies have 
noted elevated levels in both diabetes and hypertension. 
Our study clearly shows that NO turnover has a definitive 
influence on the etiology of these disorders; however, 
the non-univocal findings point to a need for robust 
multicentric studies in order to substantiate NO targeted 
therapies for these disorders.
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